Sign in
PH

Privia Health Group, Inc. (PRVA)·Q2 2025 Earnings Summary

Executive Summary

  • PRVA delivered strong Q2 with total revenue $521.2M (+23.4% y/y) and Adjusted EBITDA $29.0M (+31.6% y/y), raising FY25 guidance to above the high end for Practice Collections, GAAP Revenue, Platform Contribution, and Adjusted EBITDA .
  • Results significantly beat S&P Global consensus: revenue $521.2M vs $467.0M estimate (beat), Adjusted diluted EPS $0.24 vs $0.052 estimate (beat). Management cited broad-based value-based performance and strong ambulatory utilization as drivers (EPS and revenue estimates via S&P Global*) .
  • Key growth drivers: Implemented Providers +13.8% y/y to 5,125; attributed lives +15.2% y/y to 1.382M; Practice Collections +18.5% y/y to $862.9M .
  • Subsequent event: MSSP shared savings announcement on 8/28 led management to lift FY25 Adjusted EBITDA guidance to $113–$116M, with a full guidance update expected with Q3 results .

What Went Well and What Went Wrong

What Went Well

  • Broad-based operating momentum: Implemented Providers rose 13.8% y/y to 5,125; attributed lives +15.2% y/y; Practice Collections +18.5% to $862.9M .
  • Strong profitability and leverage: Adjusted EBITDA grew 31.6% to $29.0M; Platform Contribution +21.3% to $57.5M; Platform Contribution Margin 49.9% (vs 47.5% a year ago) .
  • Confident guidance raise: “We raised full year 2025 guidance to above the high end… for practice collections, GAAP revenue, platform contribution and adjusted EBITDA,” underpinned by provider growth and strong utilization .

What Went Wrong

  • GAAP profitability softness: Operating income fell to $3.3M from $5.1M (-34.6% y/y), and GAAP diluted EPS declined to $0.02 from $0.03; management cited higher stock-based comp ($18.8M in Q2) and bonus accruals .
  • Working capital drag: Cash from operations for 1H25 was -$16.1M, reflecting receivables growth and timing; management expects back-half shared savings cash to support year-end liquidity .
  • Capitation liabilities rose: At-risk capitation unpaid medical claims reserve increased to $99.7M from $66.4M YTD, reflecting growth in at-risk books; management reiterated disciplined risk selection and upside-only Medicaid .

Financial Results

Revenue and EPS vs prior periods

MetricQ4 2024Q1 2025Q2 2025
Total Revenue ($M)$460.9 $480.1 $521.2
GAAP Diluted EPS ($)$0.03 $0.03 $0.02
Adjusted Diluted EPS ($)$0.21 $0.22 $0.24

Profitability and margins

MetricQ4 2024Q1 2025Q2 2025
Gross Profit ($M)$106.1 $103.6 $112.8
Operating Income ($M)$5.2 $5.2 $3.3
Net Income ($M)$5.4 $6.0 $3.3
Adjusted EBITDA ($M)$24.9 $26.9 $29.0
Platform Contribution ($M)$53.2 $51.7 $57.5
Platform Contribution Margin (%)49.4% 49.1% 49.9%
Adjusted EBITDA Margin (% of Care Margin)23.1% 25.6% 25.2%

Results vs S&P Global consensus (Q2 2025)

MetricConsensus (Q2 2025)Actual (Q2 2025)
Total Revenue ($M)$467.0*$521.2
Adjusted Diluted EPS ($)$0.052*$0.24

Values marked with * are retrieved from S&P Global.

Revenue mix (disaggregated)

Revenue Source ($000s)Q4 2024Q1 2025Q2 2025
FFS – patient care312,295 311,761 331,464
FFS – administrative services33,525 32,255 35,116
Capitated revenue51,852 70,690 75,511
Shared savings44,482 47,912 60,021
Care management fees (PMPM)16,240 15,201 16,919
Other revenue2,506 2,278 2,122
Total Revenue460,900 480,097 521,153

KPIs and non-GAAP operating metrics

KPI/MetricQ4 2024Q1 2025Q2 2025
Implemented Providers (end of period)4,789 4,871 5,125
Attributed Lives (end of period)1,256,000 1,270,000 1,382,000
Practice Collections ($M)$792.5 $798.6 $862.9
Care Margin ($M)$107.7 $105.3 $115.2
Platform Contribution ($M)$53.2 $51.7 $57.5
Adjusted EBITDA ($M)$24.9 $26.9 $29.0

Guidance Changes

MetricPeriodPrevious GuidanceCurrent Guidance (8/7)Change
Implemented ProvidersFY25$5,200–$5,300; Mid–High End (5/8) High End (of range) Raised to high end
Attributed LivesFY251.30–1.40M; Unchanged (5/8) High End (of range) Raised to high end
Practice CollectionsFY25$3,150–$3,250; Mid–High End (5/8) Above High End (>$3,250) Raised above range
GAAP RevenueFY25$1,800–$1,900; Mid–High End (5/8) Above High End (>$1,900) Raised above range
Care MarginFY25$435–$445; Mid–High End (5/8) High End (of range) Raised to high end
Platform ContributionFY25$208–$218; Mid–High End (5/8) Above High End (>$218) Raised above range
Adjusted EBITDAFY25$105–$110; Mid–High End (5/8) Above High End (>$110) Raised above range
Adjusted EBITDA (update)FY25—$113–$116 (8/28) Raised post-MSSP update

Notes: Guidance includes impact of Arizona entry; assumes no other BD activity; de minimis capex; ≥80% of Adjusted EBITDA to FCF conversion .

Earnings Call Themes & Trends

TopicPrevious Mentions (Q4’24, Q1’25)Current Period (Q2’25)Trend
Business model/recurring feesEmphasized diversified value-based portfolio and consistent free cash flow conversion “Stable, recurring platform fees akin to SaaS/payments; 98% provider retention” Reinforced/stable
Utilization trendsStrong ambulatory utilization supporting FFS and VBC; assumptions prudent Strong ambulatory utilization across lines; downstream elevated trends managed in accruals Stable to favorable
MA/MSSP risk postureConservative on MA full-risk; positive but prudent MSSP accruals Continue diversified VBC; upside-only Medicaid; manage risk across programs Stable/cautious
AI/technologyAI to drive productivity and clinical prompts; scribing pilots Expanded AI in RCM and clinical workflows; Navina partnership; AI scribing Expanding adoption
Pipeline/provider additionsRobust growth engine, referral flywheel “Record first half sales; broad-based provider adds” Strengthening
RegulatoryMSSP viewed as stable; conservative on MA V28 headwinds Proposed PFS tilt to primary care seen as net positive; MSSP acceleration neutral-to-positive Slight positive tilt
IMS (Arizona)Acquired; EBITDA-positive post implementation Implementation in Q3; EBITDA positive Q4; accretive 2026 On track/positive

Management Commentary

  • “We raised full year 2025 guidance to above the high end… for practice collections, GAAP revenue, platform contribution and adjusted EBITDA,” citing provider growth, strong utilization, and VBC performance .
  • On the model: “We get paid very recurring, predictable fees for providing a tech and services platform… no different than a tech SaaS company” (with analogies to Toast/Visa/Uber) and “98% gross provider retention” .
  • On risk and payers: “We don’t take risk on costs where we cannot control those costs… we share risk with both the payers and the doctors” to align incentives and ensure sustainability .
  • On IMS: “They’ll be implemented on our platform in Q3… we continue to expect positive EBITDA from IMS in Q4” .
  • On free cash flow: “We continue to expect more than 80% of full year adjusted EBITDA to convert to free cash flow given our capital light model” .

Q&A Highlights

  • Estimate beats and sustainability: Management argued investor “identity crisis” persists, but stable platform fees and diversified VBC underpin consistent results despite sector headwinds .
  • Guidance cadence: Second-half prudence reflects timing of shared savings true-ups; doubling first-half as a “starting point” and updating after MSSP receipts .
  • Medicaid and upside-only risk: Medicaid attributed lives grew (sequential +15k), structured as upside-only shared savings; no downside risk given volatility .
  • AI deployment: Ongoing use across RCM; expanding clinical AI for suspect condition prompts and AI scribing to reduce burden and improve documentation .
  • Physician fee schedule and regulatory: Proposed fee schedule tilt to office-based/primary care seen as net positive; MSSP acceleration to higher risk does not change strategy (aim to reach Enhanced Track quickly) .

Estimates Context

  • Q2 2025 vs S&P Global consensus: Revenue $521.2M vs $467.0M estimate (beat); Adjusted diluted EPS $0.24 vs $0.052 estimate (beat). Management attributed outperformance to broad-based value-based contract performance and strong ambulatory utilization (EPS and revenue estimates via S&P Global*) .
  • Forward look: Management raised FY25 outlook on 8/7, then further increased FY25 Adjusted EBITDA to $113–$116M on 8/28 following strong MSSP results; updated full guidance to come with Q3 .

Values marked with * are retrieved from S&P Global.

Key Takeaways for Investors

  • High-quality beat and guidance raise: Strong Q2 execution with significant beats vs S&P Global consensus and FY25 guidance raised above prior ranges; subsequent 8/28 update further increased FY25 Adjusted EBITDA .
  • Durable growth drivers: Provider adds, attributed lives growth, and solid FFS utilization support continued Practice Collections and revenue expansion .
  • Margin trajectory: Platform Contribution Margin and Adjusted EBITDA margin (as % of Care Margin) remain near 50% and ~25%, respectively; management continues to target 30–35% over time via operating leverage .
  • Disciplined risk: Upside-only Medicaid, selective MA capitation, and diversified VBC portfolio mitigate payer/program volatility, supporting stable earnings quality .
  • Liquidity/optionality: $390.1M cash and no debt post-$95M IMS deployment provide capacity for disciplined BD while converting ≥80% of Adjusted EBITDA to FCF .
  • Watchlist items: GAAP operating income softness (higher SBC/bonuses), working capital seasonality in 1H cash flows, and rising capitation reserves warrant monitoring; management expects shared savings cash in 2H and remains prudent in guidance .

Notes on non-GAAP: Q2 Adjusted EPS ($0.24) and Adjusted EBITDA ($29.0M) add back stock-based compensation ($18.8M), amortization, taxes, and certain non-recurring items per reconciliations in the release .